scholarly journals Expression and Role of Epithelial Membrane Proteins in Tumorigenesis of Hormone Receptor-Positive Breast Cancer

2020 ◽  
Vol 23 (4) ◽  
pp. 385
Author(s):  
Yoon Jin Cha ◽  
Ja Seung Koo
Keyword(s):  
Breast Cancer ◽  
Membrane Proteins ◽  
Hormone Receptor ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer

The Breast ◽  
2014 ◽  
Vol 23 (3) ◽  
pp. 201-208 ◽  
Author(s):  
Eva Ciruelos ◽  
Tomás Pascual ◽  
María Luisa Arroyo Vozmediano ◽  
Marta Blanco ◽  
Luis Manso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Therapeutic Role ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting

2019 ◽  
Vol 11 ◽  
pp. 175883591985319 ◽  
Author(s):  
Anna Di Benedetto ◽  
Cristiana Ercolani ◽  
Laura Pizzuti ◽  
Domenico Angelucci ◽  
Domenico Sergi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Damage ◽  
Hormone Receptor ◽  
Breast Cancer Patients ◽  
Prognostic Role ◽  
Ki 67 ◽  
Dna Damage And Repair ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

Background: The logic behind the outcome of endocrine therapy in breast cancer has long remained poorly understood. The prognostic role of DNA damage and repair biomarkers (DDR) was explored in postmenopausal, hormone-receptor-positive breast cancer patients treated with neoadjuvant hormone therapy (NAHT). Methods: Data on 55 patients were included. The phosphorylated ataxia-teleangectasia and Rad3-related protein (pATR), phosphorylated ataxia-telangiectasia mutated (ATM) kinase, and phosphorylated H2A Histone Family Member X (γ-H2AX) were evaluated by immunohistochemistry in paired tissues collected at baseline and following NAHT. Biomarkers were considered both singularly and within signatures. Ki-67 percentage change was the primary biomarker endpoint. Classical endpoints were also considered. Results: The most favorable Ki-67 outcome was associated with the γ-H2AX/pATM signature ( p = 0.011). In models of Ki-67 reduction, ‘luminal B’ subtype, higher grade of anaplasia, and the γ-H2AX/pATM signature tested as significant ( p < 0.05 for all). Results were confirmed in multivariate analysis. No association was observed with pathologic response. An increase of ∆γ-H2AX in paired breast tissues was associated with longer event-free survival ( p = 0.027) and overall survival ( p = 0.042). In Cox models, both survival outcomes were solely affected by grade of anaplasia, with less favorable prognosis in the highest grades ( p < 0.05 for both). Conclusions: We report novel evidence of the prognostic role of DDR biomarkers on important patient outcomes in postmenopausal hormone-receptor-positive breast cancer patients treated with NAHT. If confirmed in future and adequately sized trials, our results may help inform therapeutic decisions and clarify underlying biological mechanisms.

scholarly journals Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer

2020 ◽  
Vol 14 ◽  
pp. 117822342097638
Author(s):  
Maithreyi Sarma ◽  
Yara Abdou ◽  
Ajay Dhakal ◽  
Shipra Gandhi
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
De Novo ◽  
Bone Marrow Involvement ◽  
Genomic Alterations ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

Endocrine therapy with or without CDK4/6 inhibitors is the most commonly used frontline treatment option for metastatic hormone receptor–positive breast cancer. Approximately, 25% to 30% of women may have resistance to endocrine therapy, especially in the setting of certain genomic mutations in the tumor. This prompts the need to identify those patients who may benefit from frontline chemotherapy over endocrine therapy. Here, we present a case of a patient who presented with a de novo metastatic hormone receptor–positive breast cancer with visceral involvement (including bone marrow) as well as multiple somatic genomic alterations. The patient was treated with upfront chemotherapy, resulting in clinical and radiographic response, but rapidly progressed when she was transitioned to hormonal therapy. This report focuses on the role of upfront chemotherapy in the setting of visceral crisis including bone marrow involvement, the role of genomic alterations in contributing to endocrine resistance, and the need for biomarker-driven treatment options for hormone receptor–positive breast cancer.

Sign in / Sign up

Export Citation Format

Share Document